Francesco D'AlÃ²

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8893257/publications.pdf

Version: 2024-02-01

933447 996975 17 747 10 15 citations h-index g-index papers 17 17 17 1977 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Anti CD20-based immunochemotherapy abolishes antibody response to Covid-19 mRNA vaccine in lymphoma patients vaccinated during active first line treatment. Leukemia and Lymphoma, 2022, 63, 1474-1478.	1.3	3
2	In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome. Platelets, 2021, 32, 378-382.	2.3	2
3	The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL). Leukemia and Lymphoma, 2020, 61, 1133-1139.	1.3	6
4	Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance. British Journal of Haematology, 2020, 189, e140-e144.	2.5	7
5	Vitamin D deficiency and supplementation in patients with aggressive Bâ€cell lymphomas treated with immunochemotherapy. Cancer Medicine, 2018, 7, 270-281.	2.8	44
6	Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization. Blood Cancer Journal, 2018, 8, 54.	6.2	17
7	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. Oncotarget, 2018, 9, 23443-23450.	1.8	12
8	CD 68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma. Cancer Medicine, 2016, 5, 398-406.	2.8	28
9	Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2016, 57, 628-634.	1.3	24
10	Correction of Vitamin D Deficiency in Patients with Aggressive B-Cell Lymphomas during Rituximab-Containing Chemotherapy: Impact on Outcome. Blood, 2016, 128, 3051-3051.	1.4	0
11	Quantification of DAPK1 Promoter Methylation in Bone Marrow and Peripheral Blood as a Follicular Lymphoma Biomarker. Journal of Molecular Diagnostics, 2014, 16, 467-476.	2.8	16
12	Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. Leukemia and Lymphoma, 2014, 55, 270-275.	1.3	43
13	DNMT1-interacting RNAs block gene-specific DNA methylation. Nature, 2013, 503, 371-376.	27.8	446
14	Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine. Leukemia Research, 2011, 35, 465-471.	0.8	11
15	Analysis of genome-wide methylation and gene expression induced by 5-aza- $2\hat{a}\in^2$ -deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. Leukemia and Lymphoma, 2010, 51, 2275-2284.	1.3	43
16	Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias. Current Medicinal Chemistry, 2008, 15, 1274-1287.	2.4	42
17	"Here comes the story of the Hurricane― a case report of AL cardiac amyloidosis and myocardial bridging. European Heart Journal - Case Reports, 0, , .	0.6	3